The acquisition battle between global pharmaceutical giants Pfizer and Novo Nordisk over the bio company Metsera is heating ...

We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week’s best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Dow Jones Top Company Headlines at 1 AM ET: Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk | BDO's ... Novo Nordisk and Pfizer are showing some desperation in their gloves-off ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Pfizer files lawsuit against Metsera and its directors & Novo Nordisk in the Delaware Court of Chancery for breach of merger agreement: New York Monday, November 3, 2025, 09:00 Hr ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Metsera currently has no products on the market, but is developing oral and injectable treatments for obesity and diabetes.

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.